Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2019
Implementation of “coverage with evidence development” drug approval strategies found lacking
15 July 2019 - Lessons from early deployments in The Netherlands. ...
Posted by Michael Wonder on 15 Jul 2019
The FDA disagrees with its own expert panels how often?
15 July 2019 - As the FDA grapples with rising pressure to approve new medicines more quickly, a new analysis ...
Posted by Michael Wonder on 11 Jul 2019
Reforming the Orphan Drug Act for the 21st century
11 July 2019 - The pharmaceutical market has undergone radical changes, including markedly increased prices for rare-disease drugs. ...
Posted by Michael Wonder on 10 Jul 2019
Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods
10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...
Posted by Michael Wonder on 10 Jul 2019
A Supreme Court ruling may have made it harder to get some info from the FDA
9 July 2019 - Anyone seeking certain information about a medicine from the FDA may have a harder time getting ...
Posted by Michael Wonder on 10 Jul 2019
New committee brings diverse patient, family, and caregiver voices to CADTH
10 July 2019 - Following a nationwide call for nominations, CADTH is pleased to announce the membership of its new ...
Posted by Michael Wonder on 01 Jul 2019
UK’s drug-buying agency CEO: Why we like to say ‘yes’
1 July 2019 - While more than 100 medicines sit on Pharmac's waiting list, some for 10 years, the UK's own ...
Posted by Michael Wonder on 29 Jun 2019
NICE explores extending its use of data to inform its guidance
25 June 2019 - NICE has revised its earlier press release on the use of real world data to inform ...
Posted by Michael Wonder on 16 Jun 2019
How to deal with the inevitable: generating real-world data and using real-world evidence for HTA purposes – from theory to action
14 June 2019 - Real-world evidence, derived from real-world data, is already used, to some extent, for health technology assessment purposes. ...
Posted by Michael Wonder on 12 Jun 2019
The Cancer Drugs Fund in practice and under the new framework
12 June 2019 - The Cancer Drugs Fund was established in 2010 to improve access to treatments not routinely available. ...
Posted by Michael Wonder on 12 Jun 2019
Behind the scenes at the PBAC
11 June 2019 - Outgoing RACGP representative Rashmi Sharma pulls back the curtain after 10 years on the Pharmaceutical Benefits Advisory ...
Posted by Michael Wonder on 03 Jun 2019
Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000
3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...
Posted by Michael Wonder on 02 Jun 2019
Campaign wants patients to have more influence on PBS
3 June 2019 - Australian patients should be given greater say in the medicines that receive government reimbursement as consumers ...
Posted by Michael Wonder on 30 May 2019
Use of real world data sources for Canadian drug pricing and reimbursement decisions: stakeholder views and lessons for other countries
29 May 2019 - Canada has a long history of the use of clinical evidence to support health care decision making. ...
Posted by Michael Wonder on 29 May 2019
Cost effectiveness analysis in the context of US commercial health insurance
29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...